Compare Archer-Daniels-Midland Co (ADM) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs CVS Health Corp — how do they compare? Archer-Daniels-Midland Co trades at $80.99 (market cap $38.79B), while CVS Health Corp trades at $93.71 (market cap $122.36B). The key difference: CVS Health Corp is far larger — about 3.2× Archer-Daniels-Midland Co's market cap, and CVS Health Corp pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| ADM | CVS | |
|---|---|---|
Market Cap | $38.79B | $122.36B |
Sector | Consumer Staples | Health |
52-Week High | $87.32 | $110.60 |
52-Week Low | $56.00 | $64.88 |
Enterprise Value | $47.04B | $184.71B |
Dividend Yield | 2.58% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $76.59, down 1.19% with a bearish technical signal despite recent earnings beats. The company raised its 2026 outlook after strong Q2 results driven by biofuels and crushing margins. Valuation appears reasonable with P/E of 20.93 and P/S of 0.45, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Analyst consensus is mixed with 33% buy ratings but a $88 price target suggesting 15% upside.
The stock offers value with solid dividends and improved cash flow, but faces execution risks and revenue pressure. Near-term catalysts include Q3 earnings and continued biofuels strength, while competitive pressures and margin compression remain concerns. The current price near support at $76 provides a potential entry point for long-term investors.
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
